HK1104295A1 - Tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs) - Google Patents

Tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs)

Info

Publication number
HK1104295A1
HK1104295A1 HK07109577.5A HK07109577A HK1104295A1 HK 1104295 A1 HK1104295 A1 HK 1104295A1 HK 07109577 A HK07109577 A HK 07109577A HK 1104295 A1 HK1104295 A1 HK 1104295A1
Authority
HK
Hong Kong
Prior art keywords
improved
gpcrs
ligands
protein coupled
coupled receptors
Prior art date
Application number
HK07109577.5A
Other languages
English (en)
Inventor
K Paulini
M Gerlach
E Gunther
E Polymeropoulos
S Baasner
P Schmidt
R Kuhne
A Soderhall
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HK1104295A1 publication Critical patent/HK1104295A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK07109577.5A 2004-07-14 2007-09-04 Tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs) HK1104295A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58796904P 2004-07-14 2004-07-14
DE102004033902A DE102004033902A1 (de) 2004-07-14 2004-07-14 Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
US68317805P 2005-05-20 2005-05-20
PCT/EP2005/007255 WO2006005484A1 (de) 2004-07-14 2005-07-05 Neue tetrahydrocarbazolderivate mit verbesserter biologischer wirkung und verbesserter löslichkeit als liganden für g-protein gekoppelte rezeptoren (gpcr's)

Publications (1)

Publication Number Publication Date
HK1104295A1 true HK1104295A1 (en) 2008-01-11

Family

ID=35045230

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07109577.5A HK1104295A1 (en) 2004-07-14 2007-09-04 Tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs)

Country Status (26)

Country Link
US (2) US7375127B2 (es)
EP (2) EP1765776B1 (es)
JP (1) JP4746617B2 (es)
KR (1) KR100888895B1 (es)
CN (1) CN1997629B (es)
AR (1) AR050347A1 (es)
AT (1) ATE406352T1 (es)
AU (1) AU2005261930B2 (es)
BR (1) BRPI0513209A (es)
CA (1) CA2565850C (es)
CY (1) CY1110415T1 (es)
DE (2) DE102004033902A1 (es)
DK (1) DK1765776T3 (es)
ES (1) ES2315887T3 (es)
HK (1) HK1104295A1 (es)
HR (1) HRP20080533T3 (es)
IL (1) IL179067A (es)
MX (1) MXPA06014447A (es)
NO (1) NO20070688L (es)
NZ (1) NZ551314A (es)
PL (1) PL1765776T3 (es)
PT (1) PT1765776E (es)
RS (1) RS50684B (es)
SI (1) SI1765776T1 (es)
TW (1) TWI316933B (es)
WO (1) WO2006005484A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371336B2 (en) 2002-09-24 2008-05-13 E.I. Du Pont Nemours And Company Water dispersible polyanilines made with polymeric acid colloids for electronics applications
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US9175211B2 (en) * 2010-03-03 2015-11-03 Universal Display Corporation Phosphorescent materials
MX347038B (es) * 2011-02-23 2017-04-10 Massachusetts Inst Technology Proteínas de membrana solubles en agua y métodos para la preparación y uso de las mismas.
ES2753539T3 (es) 2015-05-18 2020-04-13 Nerre Therapeutics Ltd Antagonista del receptor NK-1/NK-3 para el tratamiento de los sofocos
SI3765024T1 (sl) 2018-03-14 2024-05-31 KaNDy Therapeutics Limited Nova farmacevtska formulacija, ki vsebuje dvojne antagoniste receptorja NK-1/NK-3

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1418703A (en) * 1973-06-02 1975-12-24 Pfizer Ltd 3-alkyl-9-substituted-1,2,3,4-tetrahydrocarbazoles
DE3786030T2 (de) 1986-03-27 1993-12-02 Merck Frosst Canada Inc Tetrahydrocarbazole Ester.
EP0603432B1 (en) 1992-12-18 1998-10-21 Smithkline Beecham Plc Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
US5607939A (en) 1994-04-28 1997-03-04 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
UY23948A1 (es) 1995-02-08 2001-10-25 Takeda Chemical Industries Ltd Derivados de anillos condensados de tiofeno su producción y uso.
WO1997014697A1 (en) 1995-10-19 1997-04-24 Takeda Chemical Industries, Ltd. Thienopyridine derivatives as gonadotropin releasing hormone antagonists
AU7333496A (en) 1995-10-19 1997-05-07 Takeda Chemical Industries Ltd. Quinoline derivatives as gnrh antagonists
US6200957B1 (en) 1995-12-14 2001-03-13 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
KR19990072124A (ko) 1995-12-14 1999-09-27 애쉬톤 왈레이스 티 고나도트로핀 방출 호르몬의 길항제
CA2240115A1 (en) 1995-12-14 1997-06-19 Wallace T. Ashton Antagonists of gonadotropin releasing hormone
WO1997041126A1 (en) 1996-04-26 1997-11-06 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their production and use
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
EP0882736A1 (en) * 1997-06-02 1998-12-09 Laboratoire Theramex S.A. LH-RH peptide analogues, their uses and pharmaceutical compositions containing them
CA2292605A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP0986557A4 (en) 1997-06-05 2001-03-14 Merck & Co Inc GONADOLIBERIN ANTAGONISTS
WO1998055116A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19728737C1 (de) 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
AU1124399A (en) 1997-10-28 1999-05-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999051231A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1070064A1 (en) 1998-04-02 2001-01-24 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2366615A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
CA2367113A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
US20020065309A1 (en) 1999-08-04 2002-05-30 Ge Peng Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
CA2455871A1 (en) 2001-08-02 2003-02-20 Fabio C. Tucci Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists.
EP1453803A2 (de) 2001-12-14 2004-09-08 Zentaris GmbH Tetrahydrocarbazolderivate als liganden für g-protein gekoppelte rezeptoren (gpcr)
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
GB0206219D0 (en) 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
WO2005033099A2 (en) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof

Also Published As

Publication number Publication date
KR100888895B1 (ko) 2009-03-17
KR20070035036A (ko) 2007-03-29
RS50684B (sr) 2010-06-30
US20060014818A1 (en) 2006-01-19
DE102004033902A1 (de) 2006-02-16
BRPI0513209A (pt) 2008-04-29
IL179067A (en) 2013-08-29
CY1110415T1 (el) 2015-04-29
US7375127B2 (en) 2008-05-20
US8067456B2 (en) 2011-11-29
HRP20080533T3 (en) 2008-12-31
IL179067A0 (en) 2007-03-08
CA2565850C (en) 2011-05-10
PL1765776T3 (pl) 2009-01-30
TWI316933B (en) 2009-11-11
EP1995238A2 (de) 2008-11-26
NO20070688L (no) 2007-03-26
TW200616955A (en) 2006-06-01
CN1997629B (zh) 2011-08-03
JP2008505947A (ja) 2008-02-28
NZ551314A (en) 2009-09-25
EP1995238A3 (de) 2009-09-02
ES2315887T3 (es) 2009-04-01
JP4746617B2 (ja) 2011-08-10
PT1765776E (pt) 2008-11-04
MXPA06014447A (es) 2007-03-01
AU2005261930B2 (en) 2008-12-11
US20080280965A1 (en) 2008-11-13
ATE406352T1 (de) 2008-09-15
WO2006005484A1 (de) 2006-01-19
EP1765776B1 (de) 2008-08-27
EP1765776A1 (de) 2007-03-28
AR050347A1 (es) 2006-10-18
DK1765776T3 (da) 2008-12-15
SI1765776T1 (sl) 2008-12-31
CA2565850A1 (en) 2006-01-19
AU2005261930A1 (en) 2006-01-19
CN1997629A (zh) 2007-07-11
DE502005005206D1 (de) 2008-10-09

Similar Documents

Publication Publication Date Title
HK1104295A1 (en) Tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs)
IL200851A0 (en) Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors
ZA200800405B (en) Pyrisazinone derivatives as thyroid hormone receptor agonists
TWI318626B (en) Indole derivatives exhibiting pgd2 receptor antagonism
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
IL179737A0 (en) Indole derivatives as histamine receptor antagonists
EP2650009B8 (en) Screening methods using G-protein coupled receptors and related compositions
IL188039A0 (en) Oxindole derivatives
HK1123554A1 (en) Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
EP2370098A4 (en) ANTIBODIES FOR GUANYLYLCYCLASE RECEPTORS
EP1940843A4 (en) UNSATURATED HETEROCYCLIC DERIVATIVES
HK1132740A1 (en) Substituted oxindole derivatives and their use as vasopressin receptor ligands
PL1802307T3 (pl) Pochodne pirolidyny jako ligandy receptorów histaminowych
PL2568045T3 (pl) Zmutowane receptory sprzężone z białkiem g i sposoby ich wytwarzania
ZA200604791B (en) Hydronopol derivatives as agonists on human ORL1 receptors
HK1111698A1 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
IL182528A0 (en) Purine derivatives for use as adenosin a-2a receptor antagonists
IL184433A0 (en) 5-aminoindole derivatives
HK1095808A1 (zh) 硫代聯芳基甲基亞磺酰基衍生物
GB2423085B (en) Ligands for G-protein coupled receptors
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
IL161626A0 (en) Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
ZA200609436B (en) Novel tetrahydrocarbazole derivates with improved biological action and improved solubility as ligands for G-Protein coupled receptors (GPCRS)
TWI365186B (en) Indole derivatives
TH102377B (th) Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of g-protein couples receptors (gpcrs)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150705